The long-term goal is to use genetics and epidemiology to identify targets for prevention of colon cancer. The application is on prostaglandin biosynthesis as a promising target, because aspirin prevents some cases of colon cancer. The hypothesis is that genetic variation in prostaglandin production may mimic aspirin effects and shed light on preventive mechanisms. Work will focus on naturally-occurring mutations in people and targeted mutations in mice in a nuclear prostaglandin pathway defined by: cytosolic phospholipase A prostaglandin H synthase 2 (PTGS2/Cox-2), hematopoietic prostaglandin D synthase (H-PGDS), and peroxisome proliferator-activated receptor gamma. The project builds on discovery among 10 percent of African Americans of a PTGS2/Cox-2 mutation (Val5llAla) near the active site of the enzyme.
Specific aims are to: (1) conduct case-control analyses on prevalence of colorectal adenomas and cancer in relation to genetic variants in PTGS2/Cox-2 and H-PGDS; (2) assess human interindividual variation in PTGS2/Cox-2 activity in relation to the Va151 1 Ala enzyme variant; (3) develop in vitro expression assays for novel variants identified in H-PGDS; and (4) develop a knockout mouse model of variation in H-Pgds to complement human epidemiologic studies. Three case-control studies will be used to assess effects of genetic variation on colon neoplasms: a Kaiser sigmoidoscopy study of adenomas (1,700 subjects); a Univ. of North Carolina colonoscopy study of adenomas (800 subjects); and African American cancer cases and controls (roughly 400) from the Multiethnic Cohort Study. Results may lead to better understanding of protective mechanisms involving aspirin and nonsteroidal anti-inflammatory drugs.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA073403-06
Application #
6522379
Study Section
Epidemiology and Disease Control Subcommittee 2 (EDC)
Program Officer
Crowell, James A
Project Start
1996-09-30
Project End
2006-07-31
Budget Start
2002-08-01
Budget End
2003-07-31
Support Year
6
Fiscal Year
2002
Total Cost
$258,589
Indirect Cost
City
Torrance
State
CA
Country
United States
Zip Code
90502
Tippin, Brigette L; Kwong, Alan M; Inadomi, Michael J et al. (2014) Intestinal tumor suppression in ApcMin/+ mice by prostaglandin D2 receptor PTGDR. Cancer Med 3:1041-51
Tippin, Brigette L; Levine, A Joan; Materi, Alicia M et al. (2012) Hematopoietic prostaglandin D synthase (HPGDS): a high stability, Val187Ile isoenzyme common among African Americans and its relationship to risk for colorectal cancer. Prostaglandins Other Lipid Mediat 97:22-8
Kwong, Alan M; Tippin, Brigette L; Materi, Alicia M et al. (2011) High dietary niacin may increase prostaglandin formation but does not increase tumor formation in ApcMin/+ mice. Nutr Cancer 63:950-9
Lin, Henry J; Johansson, Ann Sofie; Stenberg, Gun et al. (2003) Naturally occurring Phe151Leu substitution near a conserved folding module lowers stability of glutathione transferase P1-1. Biochim Biophys Acta 1649:16-23
Lin, Henry J; Zhou, Haiyan; Dai, Aihua et al. (2002) Glutathione transferase GSTT1, broccoli, and prevalence of colorectal adenomas. Pharmacogenetics 12:175-9
Lin, Henry J; Lakkides, Karen M; Keku, Temitope O et al. (2002) Prostaglandin H synthase 2 variant (Val511Ala) in African Americans may reduce the risk for colorectal neoplasia. Cancer Epidemiol Biomarkers Prev 11:1305-15
Delfino, R J; Sinha, R; Smith, C et al. (2000) Breast cancer, heterocyclic aromatic amines from meat and N-acetyltransferase 2 genotype. Carcinogenesis 21:607-15
Delfino, R J; Smith, C; West, J G et al. (2000) Breast cancer, passive and active cigarette smoking and N-acetyltransferase 2 genotype. Pharmacogenetics 10:461-9
Lin, H J; Probst-Hensch, N M; Louie, A D et al. (1998) Glutathione transferase null genotype, broccoli, and lower prevalence of colorectal adenomas. Cancer Epidemiol Biomarkers Prev 7:647-52
Lin, H J; Probst-Hensch, N M; Hughes, N C et al. (1998) Variants of N-acetyltransferase NAT1 and a case-control study of colorectal adenomas. Pharmacogenetics 8:269-81